plerixafor / Generic mfg., Sanofi  >>  Phase 2
Welcome,         Profile    Billing    Logout  

29 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
plerixafor / Generic mfg.
LEONARDO, NCT05411575 / 2021-001245-13: Plerixafor in Acute Respiratory Distress Syndrome Related to COVID-19 (Phase IIb)

Withdrawn
2b
150
Europe
Plerixafor 20 MG/ML [Mozobil], Placebo
4Living Biotech
COVID-19 Acute Respiratory Distress Syndrome, COVID-19
10/22
10/22
2010-023029-39: Plerixafor MM02 - Plerixafor plus G-CSF after chemotherapy for the mobilization of Peripheral Blood Stem Cells (PBSCs) in Multiple Myeloma (MM) patients undergoing Autologous Stem Cell Transplantation (ASCT) Plerixafor in associazione al fattore di crescita granulocitario (G-CSF) dopo chemioterapia per la mobilizzazione di cellule staminali nel sangue periferico (PBSCs) in pazienti con mieloma multiplo (MM) candidati a trapianto di cellule staminali autologhe (ASCT)

Ongoing
2
37
Europe
Solution for injection, Powder and solvent for solution for injection, Powder for solution for injection, Mozobil, GRANOCYTE 34*1F 33,6MIU+F 1ML, GRANULOKINE 30*1FL 30MU 1ML, ENDOXAN BAXTER*INIET 1FL 1G
AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI, Genzyme - fornitura gratuita IMP1
multiple myeloma mieloma multiplo, multiple myeloma mieloma multiplo, Diseases [C] - Cancer [C04]
 
 
2014-004272-29: Phase II clinical trial to evaluate safety and efficacy of mobilisation and collection of CD34+ cells after treatment with plerixafor and filgrastim in patients with Fanconi anaemia for subsequent transduction with a lentiviral vector carrying the FANCA gene and reinfusion into the patient

Ongoing
2
20
Europe
Mozobil, Neupogen, Solution for injection, Solution for injection in pre-filled syringe, Mozobil, Neupogen
Great Ormond Street Hospital NHS foundation Trust, European Commission- FP7 Grant
Fanconi Anaemia, A type of bone marrow failure syndrome, Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
 
 
2009-014136-37: A pilot study on the safety and efficacy of haemopoietic stem cell mobilization (CD34+ cells) with MOZOBIL ± G-CSF, in adult patients diagnosed with beta-thalassaemia major.

Ongoing
2
20
Europe
Granulokine G-CSF, Mozobil, Mozobil
University of Washington
Beta-thalassaemia major
 
 
2010-023436-16: The feasibility and efficacy of subcutaneous and intravenous Plerixafor for mobilization of peripheral blood stem cells in allogeneic HLA–identical sibling donors: a randomized phase II study.

 
2
120
Europe
plerixafor, hematopoietic stem cells, HPCs, MOZOBIL, MOZOBIL
HOVON Foundation, , HOVON, Genzyme
stem cell mobilization
 
 
NCT05007652: A Study of KRN125 in Patients With Multiple Myeloma and Malignant Lymphoma

Completed
2
64
Japan
KRN125(pegfilgrastim), PLR001(plerixafor), KRN8601(filgrastim), PLR001(plerixafor)
Kyowa Kirin Co., Ltd.
Multiple Myeloma and Malignant Lymphoma
10/22
10/22
NCT05445128: Study of MGTA-145 and Plerixafor in Patients With Sickle Cell Disease

Terminated
2
1
US
MGTA-145, Plerixafor
Ensoma, bluebird bio
Sickle Cell Disease
12/22
02/23
NCT03547830: Plerixafor/G-CSF as Additional Agents for Conditioning Before HSCT in CGD Patients

Recruiting
2
17
RoW
Plerixafor, Gcsf
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Chronic Granulomatous Disease
01/23
01/23
NCT04177810: Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer

Completed
2
25
US
Cemiplimab, REGN-2810, LIBTAYO, Plerixafor, AMD3100, MOZOBIL
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Genzyme, a Sanofi Company, American Association for Cancer Research, National Cancer Institute (NCI)
Metastatic Pancreatic Cancer
03/23
05/23
NCT04817345: Peripheral Blood Stem Cell Collection From Patients With Sickle Cell Disease (SCD) Using Plerixafor

Withdrawn
2
15
NA
Plerixafor, Mozobil ™
St. Jude Children's Research Hospital, Doris Duke Charitable Foundation
Sickle Cell Disease
04/23
04/23
XCGD-MOBI, NCT03055247 / 2015-002356-27: Combination of Ibuprofen, G-CSF and Plerixafor as Stem Cells Mobilization Regimen in Patients Affected by X-CGD

Recruiting
2
3
Europe
Ibuprofen, Myelostim, Mozobil
IRCCS San Raffaele, Fondazione Telethon
Chronic Granulomatous Disease X-linked (X-CGD)
07/23
07/23
NCT06141304: Plerixafor Plus Donor Lymphocyte Infusion for Relapsed Acute Leukemia After Allo-HSCT

Active, not recruiting
2
28
RoW
Plerixafor, AMD3100
The First Hospital of Jilin University
Relapsed Adult ALL, Relapsed Adult AML
01/25
07/25
NCT03746080: Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma

Active, not recruiting
2
21
US
Plerixafor, AMD 3100, JM-3100, Mozobil, SDZ SID 791, Temozolomide, CCRG-81045, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temodal, Temodar, Temomedac, Whole-Brain Radiotherapy (WBRT), WBRT, whole-brain radiation therapy, whole-brain radiotherapy, Radiation Therapy, XRT, RT
Lawrence D Recht, Sanofi
Glioblastoma, Glioblastoma With Primitive Neuronal Component, Gliosarcoma, Malignant Glioma, Oligodendroglial Component Present
05/22
07/27
NCT04362293: Reduced Intensity Transplantation for Severe Sickle Cell Disease

Suspended
2
40
US
hydroxyurea, azathioprine, alemtuzumab, thioptepa, low dose total body irradiation and sirolimus, hydroxyurea, azathioprine, alemtuzumab, thiotepa, plerixafor, low dose total body irradiation, cyclophosphamide and sirolimus
St. Jude Children's Research Hospital
Sickle Cell Disease
07/24
07/25
NCT06207799: Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

Not yet recruiting
2
40
US
Elranatamab, PF-06863135, Lenalidomide, CC-5013, Revlimid™, Plerixafor, Mobozil, Melphalan, Alkeran®, Evomela, Busulfan, Busulfex™, Myleran®, G-CSF, Stem cell transplant, Allogeneic stem cell transplant, Autologous stem cell transplant, Cord blood
M.D. Anderson Cancer Center, Pfizer
Multiple Myeloma, Post-transplant MRD-guided Maintenance Therapy, Pre-transplant Purging
12/29
12/31
STAT, NCT01413100: Scleroderma Treatment With Autologous Transplant () Study

Active, not recruiting
2
21
US
Anti-Thymocyte Globulin, Antithymocyte Globulin, Antithymocyte Serum, ATG, ATGAM, ATS, Thymoglobulin, Autologous Hematopoietic Stem Cell Transplantation, Autologous Stem Cell Transplantation, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Filgrastim, Filgrastim XM02, G-CSF, Neupogen, r-metHuG-CSF, Recombinant Methionyl Human Granulocyte Colony Stimulating Factor, rG-CSF, Tbo-filgrastim, Tevagrastim, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Cellcept, MMF, Peripheral Blood Stem Cell Transplantation, PBPC transplantation, Peripheral Blood Progenitor Cell Transplantation, Peripheral Stem Cell Support, Peripheral Stem Cell Transplantation, Plerixafor, AMD 3100, JM-3100, Mozobil, SDZ SID 791, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
Fred Hutchinson Cancer Center, National Cancer Institute (NCI)
Systemic Scleroderma
08/24
08/24
NCT02570542: Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Active, not recruiting
2
59
US
leukapheresis, Plerixafor, carmustine, etoposide, cytarabine, melphalan, BEAM chemotherapy, Autologous Stem Cell Transplantation
Memorial Sloan Kettering Cancer Center, Columbia University, NorthShore University HealthSystem, University of Rochester, Medical College of Wisconsin, University of Nebraska, Sanofi, University Hospitals Seidman Cancer Center
Diffuse Large B-cell Lymphoma (DLBCL), Relapsed Diffuse Large B-cell Lymphoma (DLBCL), Refractory Diffuse Large B-cell Lymphoma (DLBCL)
10/24
10/24
NCT02015013: Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Recruiting
2
40
US
Filgrastim, Plerixafor
National Institute of Allergy and Infectious Diseases (NIAID)
Idiopathic CD4-Positive, T-Lymphocytopenia
10/26
10/26
ACTRN12609000116224: A study to investigate whether the combination of Mozobil and Neulasta is safe and effective for mobilization of blood stem cells for the treatment of lymphoma and multiple myeloma

Not yet recruiting
1/2
12
 
Peter MacCallum Cancer Centre, Genzyme Australasia Pty Ltd
Lymphoma, Multiple myeloma
 
 
NCI-2011-00344, NCT01318317: Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma

Active, not recruiting
1/2
8
US
Autologous Hematopoietic Stem Cell Transplantation, AHSCT, Autologous, Autologous Hematopoietic Cell Transplantation, Autologous Stem Cell Transplant, Autologous Stem Cell Transplantation, Stem Cell Transplantation, Autologous, Filgrastim, Filgrastim-aafi, G-CSF, Neupogen, Nivestym, r-metHuG-CSF, Recombinant Methionyl Human Granulocyte Colony Stimulating Factor, rG-CSF, Tevagrastim, Genetically Engineered Lymphocyte Therapy, Laboratory Biomarker Analysis, Peripheral Blood Stem Cell Transplantation, PBPC transplantation, PBSCT, Peripheral Blood Progenitor Cell Transplantation, PERIPHERAL BLOOD STEM CELL TRANSPLANT, Peripheral Stem Cell Support, Peripheral Stem Cell Transplant, Peripheral Stem Cell Transplantation, Plerixafor, AMD 3100, JM-3100, Mozobil, SDZ SID 791, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima
City of Hope Medical Center, National Cancer Institute (NCI)
Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma
10/13
12/24
FANCOLEN-1, NCT03157804 / 2011-006100-12: Lentiviral-mediated Gene Therapy of Fanconi Anemia Patients Subtype A

Completed
1/2
9
Europe
IV administration of Genetically Engineered Hematopoietic Stem/Progenitors Cells (HSPCs), Genetically Engineered Hematopoietic Stem/Progenitor Cells, Genetically Engineered HSPCs, Laboratory Biomarker Analysis, Filgrastim, Filgrastim XM02, Filgrastim-sndz, G-CSF (Colony Stimulating Factor), Neupogen, r-metHug-CSF, Recombinant Methionyl Human Granulocyte CSF, rG-CSF, Tbo-filgrastim, Zarxio, Plerixafor, AMD 3100, JM-3100, Mozobil, SDZ SID 791, Bone Marrow Aspiration
Hospital Infantil Universitario Niño Jesús, Madrid, Spain, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigación en Red de Enfermedades Raras (CIBERER), Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz, Hospital Vall d'Hebron, Universitat Autonoma de Barcelona
Fanconi Anemia
04/19
09/23
2019-003489-41: Study of safety and efficacy of genome-edited hematopoietic stem and progenitor cells in sickle cell disease (SCD) Studio per valutare la sicurezza d’impiego e l’efficacia di cellule staminali e progenitrici ematopoietiche corrette con editing genomico nell’anemia falciforme (SCD)

Not yet recruiting
1/2
30
Europe
Plerixafor, -, [Plerixafor], [OTQ923], [HIX763], Solution for injection, Dispersion for infusion, Plerixafor
NOVARTIS PHARMA AG, Novartis Pharma AG
Sickle Cell Disease (SCD) Anemia falciforme (SCD), Sickle Cell Disease (SCD) Anemia falciforme (SCD), Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT06325709: Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease

Recruiting
1/2
10
US
Base-edited hematopoietic stem and progenitor cells, Busulfan, Palifermin, Filgrastim, Plerixafor
National Institute of Allergy and Infectious Diseases (NIAID)
Chronic Granulomatous Disease (CGD), X-Linked Chronic Granulomatous Disease
12/32
12/32
NCT00967785: A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

Recruiting
1/2
20
US
Mozobil (TM)
National Institute of Allergy and Infectious Diseases (NIAID)
Leukopenia, Neutropenia, Infections, Warts, Myelokathexis
06/24
06/24
ABCD-NK, NCT06158828: Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML

Recruiting
1/2
48
US
Rabbit Anti thymocyte globulin, rATG, Busulfan, Fludarabine, Thiotepa, Melphalan, Evolema, Alkeran, TCR alpha beta / CD19+ depleted haploidentical hematopoietic progenitor cell graft, TCRab/CD19+ depleted haploidentical HPC graft, memory-like natural killer cells, ML NK cells, IL-2, Plerixafor, Granulocyte Colony-Stimulating Factor, G-CSF, CliniMACS
Washington University School of Medicine, The Leukemia and Lymphoma Society, Rising Tide Foundation, St. Louis Children's Hospital Foundation
AML, Childhood, Aml, Acute Myeloid Leukemia, Pediatric, Acute Myeloid Leukemia
09/28
05/30
NCT03182426: Stem Cell Mobilization (Plerixafor) and Immunologic Reset in Type 1 Diabetes (T1DM)

Active, not recruiting
1/2
60
Canada
Plerixafor, Mozobil, Alemtuzumab, Lemtrada, Anakinra, Kineret, Etanercept, Enbrel, Liraglutide, Victoza
University of Alberta, Alberta Innovates Health Solutions
Diabetes Mellitus, Type 1
07/24
12/25
003SCD101, NCT03653247: A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease

Checkmark Initial data from PRECIZN-1 trial for autologous hematopoietic stem cell transplantation in patients with severe sickle cell disease at ASH 2021
Nov 2021 - Nov 2021: Initial data from PRECIZN-1 trial for autologous hematopoietic stem cell transplantation in patients with severe sickle cell disease at ASH 2021
Checkmark Initial data from PRECIZN-1 trial for sickle cell disease
Mar 2021 - Mar 2021: Initial data from PRECIZN-1 trial for sickle cell disease
Active, not recruiting
1/2
8
US
Plerixafor, Busulfan, BIVV003, Autologous CD34 + hematopoietic stem cells
Sangamo Therapeutics
Sickle Cell Disease
07/25
07/25
NCT05470491: Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies in People Living With HIV

Suspended
1/2
3
US
RIC, GVHD prophylaxis, allo HCT, Plerixafor, Maraviroc
National Cancer Institute (NCI)
HIV, Hematologic Malignancies
07/26
07/27
NCT05357482: Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia

Recruiting
1/2
90
US
TBI, Hydroxyurea, briquilimab, Filgrastim (G-CSF), Sirolimus, Alemtuzumab, Plerixafor
National Heart, Lung, and Blood Institute (NHLBI)
Sickle Cell Anemia, Beta Thalassemia
11/32
11/33

Download Options